Panagora Asset Management’s Achillion Pharmaceuticals ACHN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q1 | – | Sell |
-628
| Closed | -$4K | – | 2690 |
|
|
2019
Q4 | $4K | Sell |
628
-1,559,381
| -100% | -$9.03M | ﹤0.01% | 2304 |
|
|
2019
Q3 | $5.62M | Buy |
1,560,009
+67,520
| +5% | +$260K | 0.03% | 434 |
|
|
2019
Q2 | $4M | Buy |
1,492,489
+348,164
| +30% | +$1.03M | 0.02% | 562 |
|
|
2019
Q1 | $3.39M | Buy |
1,144,325
+241,485
| +27% | +$593K | 0.02% | 643 |
|
|
2018
Q4 | $1.44M | Sell |
902,840
-41,351
| -4% | -$117K | 0.01% | 915 |
|
|
2018
Q3 | $3.47M | Sell |
944,191
-294,629
| -24% | -$878K | 0.01% | 637 |
|
|
2018
Q2 | $3.5M | Buy |
1,238,820
+899,102
| +265% | +$3.06M | 0.01% | 666 |
|
|
2018
Q1 | $1.26M | Sell |
339,718
-117,995
| -26% | -$386K | 0.01% | 1074 |
|
|
2017
Q4 | $1.32M | Buy |
457,713
+427,271
| +1,404% | +$1.55M | ﹤0.01% | 1037 |
|
|
2017
Q3 | $137K | Buy |
30,442
+23,464
| +336% | +$104K | ﹤0.01% | 1814 |
|
|
2017
Q2 | $32K | Buy |
+6,978
| New | +$28K | ﹤0.01% | 2163 |
|
|
2016
Q1 | – | Sell |
-1,969
| Closed | -$21K | – | 2372 |
|
|
2015
Q4 | $21K | Sell |
1,969
-3,104
| -61% | -$28.2K | ﹤0.01% | 2141 |
|
|
2015
Q3 | $35K | Buy |
5,073
+2,084
| +70% | +$17K | ﹤0.01% | 2067 |
|
|
2015
Q2 | $26K | Buy |
+2,989
| New | +$28.3K | ﹤0.01% | 2266 |
|
Panagora Asset Management's ACHN Position: Q1 2020 in Review
Panagora Asset Management sold out of Achillion Pharmaceuticals (ACHN) in Q1 2020, closing a stake of 628 shares — an estimated $4K sold.
Panagora Asset Management first reported a position in ACHN in Q2 2015 and held it in 14 quarters. The position peaked at $5.62M in Q3 2019. 0 funds tracked by Wall St. Rank hold ACHN as of Q1 2020.
- Panagora Asset Management reported no remaining Achillion Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
- Panagora Asset Management sold 628 Achillion Pharmaceuticals shares in Q1 2020, an estimated $4K.
- Panagora Asset Management first reported a position in Achillion Pharmaceuticals in Q2 2015 and held it in 14 quarters.
- Panagora Asset Management's Achillion Pharmaceuticals position peaked at $5.62M in Q3 2019.
- 0 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q1 2020.
Based on Panagora Asset Management's 13F filing for Q1 2020, filed 14 May 2020.